Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension [PDF]
, 2015 Peer ...
Bergenstal, R. M. +7 more
core +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims The risk of diabetic nephropathy among patients with type 2 diabetes (T2D) can be reduced through optimal glycaemic control. It is not known if the pharmacological properties of long‐acting insulin analogues may reduce the risk of diabetic complications compared with neutral protamine Hagedorn (NPH) insulin.
Julia Brillinger +6 more
wiley +1 more source
BMJ Open Diabetes Research & Care, 2019 Objective With healthcare systems under increasing financial pressure from costs associated with diabetes care, it is important to assess which treatments provide clinical benefits and represent best value.
Nandu Thalange +3 more
doaj +1 more source
Atypical blood glucose response to continuous and interval exercise in a person with type 1 diabetes: a case report [PDF]
, 2017 BackgroundTherapy must be adapted for people with type 1 diabetes to avoid exercise-induced hypoglycemia caused by increased exercise-related glucose uptake into muscles. Therefore, to avoid hypoglycemia, the preexercise short-acting insulin dose must be
Alexander Mueller +16 more
core +1 more source
Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia [PDF]
, 2023 Aim: To compare nocturnal glucose profiles according to hourly plasma glucose measurements during treatment with insulin degludec and insulin glargine U100 in a cohort of people with type 1 diabetes prone to nocturnal severe hypoglycaemia.
Agesen, Rikke Mette +17 more
core +3 more sources
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims This real‐world study evaluated the effectiveness and safety of switching basal insulin (BI) to insulin glargine 300 U/mL (Gla‐300) in adults with inadequately controlled type 2 diabetes mellitus (T2DM), previously receiving basal‐supported oral therapy plus prandial insulin (BOTplus) or multiple (≥3) daily injections (MDI) of short ...
Stefan Pscherer +6 more
wiley +1 more source
Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates [PDF]
, 2014 Since its discovery and isolation, exogenous insulin has dramatically changed the outlook for patients with diabetes. However, even when patients strictly follow an insulin regimen, serious complications can result as patients experience both ...
Anderson, Daniel Griffith +9 more
core +1 more source
United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes
Drug Design, Development and Therapy, 2017 Marc Rendell1,2 1The Rose Salter Medical Research Foundation, 2The Association of Diabetes Investigators, Newport Coast, CA, USA Abstract: Insulin degludec has been the product of a sophisticated and systematic biochemical engineering program which ...
Rendell M
doaj
Pakistan Armed Forces Medical JournalObjective: To determine whether Insulin Degludec Aspart is associated with a reduced risk of hypoglycemia as compared to premixed Insulin aspart therapy in type-2 diabetes mellitus patients. Study Design: Quasi-experimental study Place and Duration
Komal Mumtaz Malik +4 more
doaj +1 more source
Сахарный диабет, 2015 Aim: The aim of this study was to evaluate the efficacy and safety of the new ultra-long-acting insulin degludec (Tresiba®) in the treatment of type 2 diabetes in routine clinical practice.Methods: This primary health care clinical observational study ...
Lyudmila Alexandrovna Suplotova +5 more
doaj +1 more source